{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T23:03:24Z","timestamp":1766012604408,"version":"build-2065373602"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2016ZX10004001"],"award-info":[{"award-number":["2016ZX10004001"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Lassa virus (LASV) is a rodent-borne arenavirus circulating in West African regions that causes Lassa fever (LF). LF is normally asymptomatic at the initial infection stage, but can progress to severe disease with multiorgan collapse and hemorrhagic fever. To date, the therapeutic choices are limited, and there is no approved vaccine for avoiding LASV infection. Adenoviral vector-based vaccines represent an effective countermeasure against LASV because of their safety and adequate immunogenicity, as demonstrated in use against other emerging viral infections. Here, we constructed and characterized a novel Ad5 (E1-, E3-) vectored vaccine containing the glycoprotein precursor (GPC) of LASV. Ad5-GPCLASV elicited both humoral and cellular immune responses in BALB\/c mice. Moreover, a bioluminescent imaging-based BALB\/c mouse model infected with GPC-bearing and luciferase-expressing replication-incompetent LASV pseudovirus was utilized to evaluate the vaccine efficacy. The bioluminescence intensity of immunized mice was significantly lower than that of control mice after being inoculated with LASV pseudovirus. This study suggests that Ad5-GPCLASV represents a potential vaccine candidate against LF.<\/jats:p>","DOI":"10.3390\/v13030484","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T22:16:54Z","timestamp":1615846614000},"page":"484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever"],"prefix":"10.3390","volume":"13","author":[{"given":"Meirong","family":"Wang","sequence":"first","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruihua","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2982-0059","authenticated-orcid":false,"given":"Yaohui","family":"Li","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changming","family":"Yu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyang","family":"Chi","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-247X","authenticated-orcid":false,"given":"Shipo","family":"Wu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shulin","family":"Liu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Xu","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory of Vaccine and Antibody Engineering, Beijing Institute of Biotechnology, Beijing 100071, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hallam, H.J., Hallam, S., Rodriguez, S.E., Barrett, A.D.T., Beasley, D.W.C., Chua, A., Ksiazek, T.G., Milligan, G.N., Sathiyamoorthy, V., and Reece, L.M. (2018). Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. NPJ Vaccines, 3.","DOI":"10.1038\/s41541-018-0049-5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.coviro.2019.06.005","article-title":"A short history of Lassa fever: The first 10-15 years after discovery","volume":"37","author":"Monath","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.idc.2019.08.002","article-title":"Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management and Prevention","volume":"33","author":"Asogun","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/DDDT.S147276","article-title":"Current research for a vaccine against Lassa hemorrhagic fever virus","volume":"12","author":"Warner","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.coviro.2019.07.006","article-title":"A review of Lassa fever vaccine candidates","volume":"37","author":"Salami","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Purushotham, J., Lambe, T., and Gilbert, S.C. (2019). Vaccine platforms for the prevention of Lassa fever. Immunol. Lett.","DOI":"10.1016\/j.imlet.2019.03.008"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lukashevich, I.S., Paessler, S., and de la Torre, J.C. (2019). Lassa virus diversity and feasibility for universal prophylactic vaccine. F1000Research, 8.","DOI":"10.12688\/f1000research.16989.1"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coviro.2018.11.001","article-title":"Arenavirus genomics: Novel insights into viral diversity, origin, and evolution","volume":"34","author":"Pontremoli","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3390\/v4102162","article-title":"Envelope glycoprotein of arenaviruses","volume":"4","author":"Burri","year":"2012","journal-title":"Viruses"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mateer, E.J., Maruyama, J., Card, G.E., Paessler, S., Huang, C., and Heise, M.T. (2020). Lassa Virus, but Not Highly Pathogenic New World Arenaviruses, Restricts Immunostimulatory Double-Stranded RNA Accumulation during Infection. J. Virol., 94.","DOI":"10.1128\/JVI.02006-19"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Schaeffer, J., Carnec, X., Reynard, S., Mateo, M., Picard, C., Pietrosemoli, N., Dillies, M.A., and Baize, S. (2018). Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007430"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/JVI.03049-15","article-title":"Inhibition of Innate Immune Responses Is Key to Pathogenesis by Arenaviruses","volume":"90","author":"Meyer","year":"2016","journal-title":"J. Virol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.4049\/jimmunol.172.5.2861","article-title":"Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells","volume":"172","author":"Baize","year":"2004","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Flatz, L., Rieger, T., Merkler, D., Bergthaler, A., Regen, T., Schedensack, M., Bestmann, L., Verschoor, A., Kreutzfeldt, M., and Bruck, W. (2010). T cell-dependence of Lassa fever pathogenesis. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1000836"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/infdis\/jix201","article-title":"A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses","volume":"215","author":"McElroy","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","article-title":"Clinical Virology of Lassa Fever in Hospitalized Patients","volume":"155","author":"Johnson","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/nm.4396","article-title":"Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever","volume":"23","author":"Mire","year":"2017","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","article-title":"Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies","volume":"133","author":"Cross","year":"2016","journal-title":"Antiviral Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.1890370102","article-title":"Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys","volume":"37","author":"McCormick","year":"1992","journal-title":"J. Med. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1517\/14712590903307388","article-title":"Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors","volume":"9","author":"Seregin","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/molbev\/msy096","article-title":"MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms","volume":"35","author":"Kumar","year":"2018","journal-title":"Mol. Biol. Evol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/molbev\/mst012","article-title":"Building phylogenetic trees from molecular data with MEGA","volume":"30","author":"Hall","year":"2013","journal-title":"Mol. Biol. Evol."},{"key":"ref_23","first-page":"275","article-title":"The rapid generation of mutation data matrices from protein sequences","volume":"8","author":"Jones","year":"1992","journal-title":"Comput. Appl. Biosci. CABIOS"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/S0140-6736(15)60553-0","article-title":"Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial","volume":"385","author":"Zhu","year":"2015","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: A single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1126\/science.aam7260","article-title":"Structural basis for antibody-mediated neutralization of Lassa virus","volume":"356","author":"Hastie","year":"2017","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Robinson, J.E., Hastie, K.M., Cross, R.W., Yenni, R.E., Elliott, D.H., Rouelle, J.A., Kannadka, C.B., Smira, A.A., Garry, C.E., and Bradley, B.T. (2016). Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun., 7.","DOI":"10.1038\/ncomms11544"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Willard, K.A., Alston, J.T., Acciani, M., and Brindley, M.A. (2018). Identification of Residues in Lassa Virus Glycoprotein Subunit 2 That Are Critical for Protein Function. Pathogens, 8.","DOI":"10.3390\/pathogens8010001"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Heinrich, M.L., Boisen, M.L., Nelson, D.K.S., Bush, D.J., Cross, R.W., Koval, A.P., Hoffmann, A.R., Beddingfield, B.J., Hastie, K.M., and Rowland, M.M. (2020). Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-72539-w"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/infdis\/jiy187","article-title":"Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models","volume":"218","author":"Guo","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3201\/eid2403.171905","article-title":"New Lineage of Lassa Virus, Togo, 2016","volume":"24","author":"Whitmer","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1016\/j.vaccine.2019.09.030","article-title":"Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs","volume":"37","author":"Maruyama","year":"2019","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of Ebola and Lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Sullivan, B.M., Sakabe, S., Hartnett, J.N., Ngo, N., Goba, A., Momoh, M., Demby Sandi, J., Kanneh, L., Cubitt, B., and Garcia, S.D. (2020). High crossreactivity of human T cell responses between Lassa virus lineages. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008352"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zapata, J.C., Medina-Moreno, S., Guzman-Cardozo, C., and Salvato, M.S. (2018). Improving the Breadth of the Host\u2019s Immune Response to Lassa Virus. Pathogens, 7.","DOI":"10.3390\/pathogens7040084"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.cell.2019.07.020","article-title":"Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization","volume":"178","author":"Hastie","year":"2019","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coi.2020.03.013","article-title":"Innovations in structure-based antigen design and immune monitoring for next generation vaccines","volume":"65","author":"Ward","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev-med-121217-094234","article-title":"Structure-Based Vaccine Antigen Design","volume":"70","author":"Graham","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.cell.2018.02.054","article-title":"Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines","volume":"172","author":"Rey","year":"2018","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.tibtech.2017.06.018","article-title":"Structure and Computation in Immunoreagent Design: From Diagnostics to Vaccines","volume":"35","author":"Gourlay","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Abreu-Mota, T., Hagen, K.R., Cooper, K., Jahrling, P.B., Tan, G., Wirblich, C., Johnson, R.F., and Schnell, M.J. (2018). Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat. Commun., 9.","DOI":"10.1038\/s41467-018-06741-w"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:36:03Z","timestamp":1760160963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["v13030484"],"URL":"https:\/\/doi.org\/10.3390\/v13030484","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2021,3,15]]}}}